sites. All individuals offered written informed consent prior to enrolment to the research. An interactive voice response program was employed to randomly assign individuals in a one:one ratio to fl udarabine plus alemtuzumab or fl udarabine monotherapy in an open label trial.
Showing posts with label PI3K Inhibitors. Show all posts
Showing posts with label PI3K Inhibitors. Show all posts
Thursday, August 23, 2012
Third Party Analysis Reveals The Unanswered Questions About Protease
This research was authorized by the institutional assessment board or ethics committee from each of the participating sites. All individuals offered written informed consent prior to enrolment to the research. An interactive voice response program was employed to randomly assign individuals in a one:one ratio to fl udarabine plus alemtuzumab or fl udarabine monotherapy in an open label trial.
sites. All individuals offered written informed consent prior to enrolment to the research. An interactive voice response program was employed to randomly assign individuals in a one:one ratio to fl udarabine plus alemtuzumab or fl udarabine monotherapy in an open label trial.
Subscribe to:
Posts (Atom)